Close
Stratified Treatment OPtimisation for HCV-1: An open-label randomised controlled trial (RCT) testing biomarker-stratified short-course first-line and re-treatment direct-acting antiviral (DAA) oral treatment regimens to cure mild chronic Hepatitis C (HCV) disease
Project Summary
New treatments for hepatitis C (HCV) can be taken for shorter periods of time, with less severe side-effects compared to previous treatments (6-12 months). Almost all people are cured with 12 weeks of treatment; it is unknown what the minimum duration of treatment could be in order to achieve cure, there have been limited investigations into shorter treatments.
The protocol has been designed as a platform protocol to look at varying (intervention) 4-6 weeks vs fixed (control) 8
weeks of first-line combined Direct Acting Antiviral (DAA) treatment with or without ribavirin for patients with mono-infection with HCV or co-infection (HIV/HCV), with genotype 1a/1b and mild liver disease.
Key Project Information
Dates: 28th November 2017 - (ongoing)
UCL lead/Principal Investigator: Dr Richard Gilson
Lead organisation: Imperial College London
Project lead: Dr Graham Cooke
Partners: MRC Clinical Trials Unit at UCL; Central and North West London NHS Foundation Trust
Location: England (multi-centre)
Funding: MRC/NIHR EME Programme
Contact: mmc-research-cnwl@nhs.net
Website: www.stop-hcv.ox.ac.uk/stop-hcv-1-trial
- Research Team
Marzia Fiorino
Dr Sarah Pett
Dr Diarmuid Nugent
Dr Binta Sultan